University of Lausanne Hospitals

chuv.ch

Total trials

118

Active

7

Phase 3

2

Total enrollment

24,142

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 1 of 1 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
68Ga-NODAGA-RGD PET/CT2

Next readouts

  • 2024-12

Top conditions

  • Obesity4
  • Stress4
  • Nasal Obstruction3
  • Knee Osteoarthritis3
  • Coronary Artery Disease3
  • Physical Activity3
  • Prostate Cancer3
  • Osteoarthritis, Knee2

Frequently asked questions about University of Lausanne Hospitals

How many clinical trials does University of Lausanne Hospitals have on ClinicalTrials.gov?
University of Lausanne Hospitals is listed as the lead sponsor on 118 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Lausanne Hospitals's trials are in Phase 3?
2 of University of Lausanne Hospitals's trials are in Phase 3, spread across 1 active drug program.
What therapeutic areas does University of Lausanne Hospitals focus on?
University of Lausanne Hospitals's most-studied conditions on ClinicalTrials.gov are Obesity, Stress, Nasal Obstruction, Knee Osteoarthritis, Coronary Artery Disease.
When are University of Lausanne Hospitals's next clinical trial readouts?
University of Lausanne Hospitals has 1 upcoming primary-completion readout tracked here; the soonest is “Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque”, expected around 2024-12.